Latest News

10.20.2009


Cellceutix Announces Acquisition of New Compound 10.19.2009


Startup pharma company runs a tight ship on path to crucial human testing 10.06.2009

Interview with George Evans, Cellceutix's CEO, at SmallCapVoice.com 10.06.2009

Breast Cancer Awareness Month Draws Investors Too 09.11.2009



Girindus America will manufacture the API for Cellceutix Corp's Kevetrin product 09.09.2009



IFCR in pact for collaborative research 08.25.2009



Cellceutix Corporation has acquired the rights to the blood pressure compound KM 732 08.20.2009



Cellceutix signs agreement with Girindus America 05.21.2009



Cellceutix Files Patent Application For Its Cancer Compound 05.14.2008



Cellceutix Obtains Initial Funding to Advance Its Head and Neck Cancer Drug

Press Releases

02.18.2010
Cellceutix Completes Successful Pre-IND Meeting With FDA for Cancer Drug 11.02.2009
Cellceutix Signs Agreement for Kevetrin(TM) Safety Studies with Toxikon Corporation 10.20.2009
Attacking Cancer with Specific Anti-Tumor Pathways 10.13.2009
Dr. Menon Selected For Expert Panel 10.06.2009
Cellceutix Compound Shows Significant Effect On Psoriasis 09.21.2009
Cellceutix's Kevetrin™ Demonstrates Significant Delay of Tumor Growth in Drug Resistant Breast Cancer 08.26.2009
Cellceutix Announces Acquisition of New Compound With High Blood Pressure Lowering Properties 08.18.2009
Cellceutix Signs Manufacturing Agreement for Kevetrin™ Active Pharmaceutical Ingredient 07.24.2009
Cellceutix Cancer Drug Shows No Significant Indications Of Toxicity -Results of acute toxicity studies in animals. 07.15.2009
Cellceutix Announces Dr. Samuel Danishefsky Joins Its Scientific Advisory Board 07.13.2009
Kevetrin™ Animal Model Testing Success Against Multi-Drug Resistant Lung Cancer 06.30.2009
Cellceutix Announces Dr. Emil Frei to be On Its Scientific Advisory Board Through June 30, 2010 05.29.2008
Cellceutix cancer compound: Crunching the numbers